Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
DVAX Stock Chart & Stats
$10.80
-$0.11(-0.86%)
At close: 4:00 PM EST
$10.80
-$0.11(-0.86%)
Day’s Range― - ―
52-Week Range$9.20 - $14.63
Previous CloseN/A
Volume272.71K
Average Volume (3M)1.76M
Market Cap
$1.28B
Enterprise Value$996.54M
Total Cash (Recent Filing)$647.82M
Total Debt (Recent Filing)$285.02M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Feb 19, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.21
Shares Outstanding117,424,965
10 Day Avg. Volume1,394,093
30 Day Avg. Volume1,759,931
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.78
Price to Sales (P/S)5.99
P/FCF Ratio27.60
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit3.63
Enterprise Value/Ebitda-38.85
Forecast
1Y Price Target
$20.50Price Target Upside89.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Share GrowthDynavax's market share in the U.S. HBV market increased to 46%, showing growth and strong market presence.
Retail Segment DemandRetail pharmacies have increased their prioritization of Heplisav, leading to a 63% share of the retail segment, suggesting strong demand.
Share Repurchase ProgramThe company's newly authorized $100 million share repurchase signals confidence in Dynavax's ability to balance research and development spending with returning capital to shareholders.
Bears Say
Financial RiskDynavax's licensing agreement with Vaxart involves significant financial commitments and future payments, bringing potential financial risk if the vaccine candidate does not meet expectations.
Sales PerformanceThird-quarter Heplisav sales of $90 million came slightly below estimates and consensus, attributed to a later start of the flu vaccination season.
Dynavax News
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.20 and its highest was $14.63 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Dynavax Technologies Corp.’s market cap is $1.28B.
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is Feb 19, 2026 which is in 68 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Oct 24, 2025. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.126 by $0.084.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is 0.04.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 117,424,965 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.21 in its last earnings report, beating expectations of $0.126. Following the earnings report the stock price went up 1.06%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Currently, no hedge funds are holding shares in DVAX
Dynavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.50 (89.81% Upside)
$20.50 (89.81% Upside)
Blogger Sentiment
Bullish
DVAX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.87%
12-Months-Change
Fundamentals
Return on Equity
-7.14%
Trailing 12-Months
Asset Growth
-10.87%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
DVAX Company Deck
DVAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic advancements in the company's pipeline and partnerships, notably with Vaxart. Despite a few concerns about potential seasonal impacts and a decrease in cash reserves, the company's overall financial health and strategic initiatives suggest a positive outlook.View all DVAX earnings summariesDVAX Stock 12 Month Forecast
Average Price Target
$20.50
▲(89.81% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―
Ownership Overview
13.92% Insiders
15.53% Mutual Funds
27.62% Other Institutional Investors
20.17% Public Companies and
Individual Investors